Development and validation of the Neuropathic Pain Symptom Inventory
暂无分享,去创建一个
Jacques Fermanian | Michel Lanteri-Minet | J. Fermanian | D. Bouhassira | N. Attal | M. Gautron | M. Lanteri-Minet | Nadine Attal | Didier Bouhassira | F. Boureau | François Boureau | Haiel Alchaar | Michèle Gautron | Etienne Masquelier | Sylvie Rostaing | Elisabeth Collin | Jacques Grisart | H. Alchaar | E. Masquelier | S. Rostaing | E. Collin | J. Grisart
[1] L. Wilkins. Quantitative sensory testing , 1993, Neurology.
[2] R. Baron,et al. Translation of symptoms and signs into mechanisms in neuropathic pain , 2003, Pain.
[3] C. Woolf,et al. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients , 1999, Pain.
[4] Misha-Miroslav Backonja,et al. Development of a Neuropathic Pain Questionnaire , 2003, The Clinical journal of pain.
[5] P. Hansson. Difficulties in stratifying neuropathic pain by mechanisms , 2003, European journal of pain.
[6] F. Boureau,et al. Study of verbal description in neuropathic pain , 1990, Pain.
[7] T. Jensen,et al. Pain phenomena and possible mechanisms in patients with painful polyneuropathy , 2003, Pain.
[8] M. Max. Is mechanism-based pain treatment attainable? Clinical trial issues. , 2000, The journal of pain : official journal of the American Pain Society.
[9] T. Jensen,et al. Lamotrigine for central poststroke pain: A randomized controlled trial , 2001 .
[10] H. Fruhstorfer,et al. Method for quantitative estimation of thermal thresholds in patients. , 1976, Journal of neurology, neurosurgery, and psychiatry.
[11] C. Cleeland,et al. Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.
[12] R. Baron. Peripheral Neuropathic Pain: From Mechanisms to Symptoms , 2000, The Clinical journal of pain.
[13] M. Bennett,et al. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs , 2001, Pain.
[14] A. Boulton,et al. A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy , 1989, Pain.
[15] T. Jessell. PAIN , 1982, The Lancet.
[16] W. Willis. Hyperalgesia and allodynia , 1992 .
[17] M. Max,et al. Mechanism-based Pain Diagnosis: Issues for Analgesic Drug Development , 2001, Anesthesiology.
[18] T. Jensen,et al. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action , 1999, PAIN®.
[19] D. Yarnitsky,et al. Clinical applications of quantitative sensory testing (QST) , 1998, Journal of the Neurological Sciences.
[20] T. Yaksh,et al. Concentration–effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain , 2001, Pain.
[21] M. Wallace,et al. Efficacy of Oral Mexiletine for Neuropathic Pain With Allodynia: A Double-Blind, Placebo-Controlled, Crossover Study , 2000, Regional Anesthesia & Pain Medicine.
[22] J. Fleiss,et al. Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.
[23] T. Yaksh,et al. Concentration–Effect Relationship of Intravenous Lidocaine on the Allodynia of Complex Regional Pain Syndrome Types I and II , 2000, Anesthesiology.
[24] D. Bouhassira,et al. Effects of IV morphine in central pain: A randomized placebo-controlled study , 2002, Neurology.
[25] C. Woolf,et al. Neuropathic pain: aetiology, symptoms, mechanisms, and management , 1999, The Lancet.
[26] R. Lipton,et al. Towards a mechanism-based classification of pain? , 1998, Pain.
[27] P. Eide,et al. Relief of post-herpetic neuralgia with the N-methyl-d-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo , 1994, Pain.
[28] D. Bouhassira,et al. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response , 2004, Neurology.
[29] M. Rowbotham,et al. The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale , 2002, The Clinical journal of pain.
[30] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.
[31] P. Eide,et al. Continuous subcutaneous administration of the N-methyl-d-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia , 1995, Pain.